Scantox Advances DuplexSeq™ Bioinformatics with Enhanced Cloud Mutagenesis App

Scantox Enhances DuplexSeq™ Bioinformatics

Scantox Group, a leader in preclinical research, has made a significant advancement in its DuplexSeq™ bioinformatics platform by introducing a new cloud-based application designed for mutagenesis. This announcement was made on May 12, 2026, highlighting the company's commitment to enhancing its sequencing services and providing robust tools for clients.

The newly launched Scantox DuplexSeq application is hosted on an upgraded bioinformatics infrastructure, which allows for improved error correction during sequencing processes crucial for genomic safety. Matt Tate, PhD, Chief Business Development Officer of Scantox, emphasized that the upgraded platform is faster and more accessible, promising clients a heightened level of confidence in their genomic assessments. He stated, “DuplexSeq™ is now a primary methodology for error correction in sequencing within the framework of non-clinical mutagenesis evaluation, and it is now positioned to deliver on that promise at scale.”

Seamless Transition to Cloud

The transition to LatchBio’s platform was stated to be smooth and efficient, as explained by Clint Valentine, Vice President of Operations at Fulcrum Genomics. The original DuplexSeq™ pipeline was created with robust scientific standards, and the migration to the cloud infrastructure has maintained the integrity of the pipe while enhancing its capabilities. Valentine noted that tests conducted on original validation datasets confirmed the equivalence of results and the consistent performance of the pipeline. “The platform is better, and the science remains unchanged,” he added.

Scantox selected LatchBio after a thorough evaluation of available bioinformatics platforms due to LatchBio's user experience and adaptiveness to regulated non-clinical science. The new application allows clients to execute a validated mutation analysis pipeline at the click of a button, streamline data project management, enhance data visualization, and create customized reports. Furthermore, clients can upload historical study data directly to the new platform, ensuring a smooth transition for ongoing projects.

Regulatory Assurances

Kyle Giffin, Chief Operating Officer of LatchBio, stressed the importance of data integrity, traceability, and audit readiness in the regulated environment where DuplexSeq™ clients operate. LatchBio has been designed to meet strict regulatory standards, featuring 21 CFR Part 11 controls, unalterable audit trails, and SOC 2 Type II certified infrastructure, fostering trust and compliance among its users.

The DuplexSeq™ reagent kits are already available, with expanded commercial availability slated for the third quarter of 2026. In addition, Scantox is set to host a live webinar to guide users on the integration of the new platform, with registration open on their official website.

About Scantox

Founded in 1977, Scantox is an integrated contract research organization (CRO) that supports sponsors from drug discovery through nonclinical development toward attaining New Molecular Entity (NME) status. The company operates in Denmark, Sweden, Austria, and the United Kingdom, and focuses on high-quality, regulatory-ready data across various disciplines including pharmacology, toxicology, and genetic safety assessments. Scantox is particularly recognized for its expertise in central nervous system pharmacology and capabilities in genetic toxicology, including the Big Blue® transgenic rodent assays and DuplexSeq™ mutagenesis testing. Scantox is part of Impilo, a leading Nordic health investment firm. For more information, visit Scantox.

About LatchBio

LatchBio, located in San Francisco, is dedicated to building data infrastructure and pipelines for the biotechnology sector. The company specializes in providing client-focused bioinformatics platforms with enterprise-level security, ensuring compliance with 21 CFR Part 11 regulations and featuring SOC 2 Type II certified infrastructure, facilitating seamless operations in research and genetic analysis. More details can be found at LatchBio.

About Fulcrum Genomics

Fulcrum Genomics offers bioinformatics consulting services and software development for genomics. Established by leaders in the fields of genomics and computational biology, Fulcrum partners with biotechnology and pharmaceutical organizations to build and maintain production-level bioinformatics systems. For further insights, visit Fulcrum Genomics.